Global Kidney Cancer Drugs Market Size Study, by Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, Wilms Tumor, Renal Sarcoma), by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), by Drug Class (Angiogenesis Inhibitors, Monoclonal Antibo

Global Kidney Cancer Drugs Market Size Study, by Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, Wilms Tumor, Renal Sarcoma), by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), by Drug Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy), by Route of Administration (Oral, Intravenous, Subcutaneous), by End Use (Hospital Pharmacies, Retail Pharmacies, Others), and Regional Forecasts 2022–2032

The global kidney cancer drugs market was valued at USD 6.25 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.9% over the forecast period from 2024 to 2032. This growth is primarily driven by advancements in immunotherapy and targeted therapies, which are revolutionizing treatment outcomes for patients with kidney cancer. Additionally, the increasing prevalence of renal cell carcinoma (RCC), coupled with the rise in healthcare expenditure, is fostering market growth.

Renal Cell Carcinoma (RCC) is the leading type of kidney cancer, contributing to 85.8% of market revenue in 2023. This is attributed to aging demographics, lifestyle-related risk factors, and improvements in diagnostic techniques enabling early detection. Immunotherapies and targeted treatments are anticipated to expand further, offering a more patient-centric approach with minimized side effects compared to traditional chemotherapies.

Geographically, North America dominated the kidney cancer drugs market in 2023, supported by robust healthcare infrastructure and access to cutting-edge treatments. The Asia-Pacific region, however, is projected to grow at the fastest rate, owing to increasing healthcare access and awareness campaigns. Rising adoption of biosimilars and innovative drug pipelines also present promising opportunities for market players in emerging economies.

Major market players included in this report are:
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Helsinn Healthcare SA
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG

The detailed segments and sub-segments of the market are explained below:

By Type
• Renal Cell Carcinoma (RCC)
• Transitional Cell Cancer
• Wilms Tumor
• Renal Sarcoma

By Therapy
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Other Therapies

By Drug Class
• Angiogenesis Inhibitors
• Monoclonal Antibodies
• mTOR Inhibitors
• Cytokine Immunotherapy (IL-2)
• Other Drug Classes

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By End Use
• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways
• Market estimates & forecasts for 10 years from 2022 to 2032.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approaches.
• Analysis of the competitive structure of the market.
• Demand-side and supply-side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.